Clinical study on treatment of primary liver cancer by Aidi injection combined with cool-tip radiofrequency ablation.
- Author:
Hai-Zhou LOU
1
;
Hong-Ming PAN
;
Wei JIN
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; CD4-CD8 Ratio; Carcinoma, Hepatocellular; immunology; therapy; Catheter Ablation; methods; Combined Modality Therapy; Drugs, Chinese Herbal; administration & dosage; therapeutic use; Female; Humans; Infusions, Intravenous; Liver Neoplasms; immunology; therapy; Male; Middle Aged; Phytotherapy; Treatment Outcome
- From: Chinese Journal of Integrated Traditional and Western Medicine 2007;27(5):393-395
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the therapeutic efficacy and adverse reactions of Aidi Injection (AI) combined with percutaneous cool-tip radiofrequency ablation (CRFA) in treatment of primary liver cancer and to explore its effect on immune function.
METHODSEighty-nine patients with primary liver cancer at middle-late stage were assigned to the control group with CRFA alone and the treatment group treated with CRFA and intravenous dripping of AI 50 mL once every day for succesive 20 days.
RESULTSCompared with those before treatment, the alanine aminotransferase (ALT) and albumin (ALB) levels showed no marked change, and CD4 subgroup of T lymphocyte and CD4/CD8 ratio elevated in the treatment group (P<0.01), while the ALT level elevated (P<0.05), ALB level decreased (P < 0.01), CD4 and CD4/CD8 ratio showed no change in the control group. The relapse rate was 20.0% (3/15) in patients with tumor more than 3 cm in diameter of the treatment group, which was obvious lower than that in the control group (55.0%, 11/20, P < 0.05).
CONCLUSIONAI treatment could relieve the impairment of CRFA on hepatic function, improve immune function and reduce relapse rate in patients with primary liver cancer.
